Loading company…
Wuhan medical technology firm offering laboratory services and in vitro diagnostic products, listed on the Shanghai Stock Exchange in 2016.
Based in Wuhan, China and established in 2004, Wuhan Thalys Medical Technology Inc. generates revenue from in vitro diagnostic products and medical laboratory services. Its products include self-developed analyzers and reagents, such as the AIFA-200 immunofluorescence analyzer, along with agent products from Siemens and other brands. The company has three branches and two offices, and lists partners including PKU Healthcare IT Co., Ltd., Goldman Sachs Remit Gold and illumina. It was listed on the Shanghai Stock Exchange in October 2016.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in